Published in J Clin Microbiol on November 01, 2004
Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type. J Clin Microbiol (2009) 1.48
Population diversity among Bordetella pertussis isolates, United States, 1935-2009. Emerg Infect Dis (2012) 1.45
Small mutations in Bordetella pertussis are associated with selective sweeps. PLoS One (2012) 1.35
Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics (2010) 1.33
Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics (2008) 1.26
Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PLoS One (2007) 1.26
Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains. Clin Vaccine Immunol (2007) 1.05
Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol (2007) 1.04
Effect of vaccination on Bordetella pertussis strains, China. Emerg Infect Dis (2010) 0.98
Genetic analysis of Bordetella pertussis isolates from the 2008-2010 pertussis epidemic in Japan. PLoS One (2013) 0.94
Differential expression of type III effector BteA protein due to IS481 insertion in Bordetella pertussis. PLoS One (2011) 0.94
Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model. Clin Vaccine Immunol (2010) 0.93
The Bordetella pertussis model of exquisite gene control by the global transcription factor BvgA. Microbiology (2012) 0.91
Immunodominance in mouse and human CD4+ T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin. Infect Immun (2008) 0.89
Analytical verification of a PCR assay for identification of Bordetella avium. J Clin Microbiol (2005) 0.89
Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009. J Clin Microbiol (2012) 0.86
Strain variation among Bordetella pertussis isolates circulating in Poland after 50 years of whole-cell pertussis vaccine use. J Clin Microbiol (2011) 0.82
Roads to the development of improved pertussis vaccines paved by immunology. Pathog Dis (2015) 0.81
Antibody responses to individual Bordetella pertussis fimbrial antigen Fim2 or Fim3 following immunization with the five-component acellular pertussis vaccine or to pertussis disease. Clin Vaccine Immunol (2012) 0.80
Variation in Bordetella pertussis Susceptibility to Erythromycin and Virulence-Related Genotype Changes in China (1970-2014). PLoS One (2015) 0.78
Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis. BMC Microbiol (2009) 0.78
Multilocus Sequence Analysis of Housekeeping Genes and Antigenic Determinant Genes in Bordetella pertussis Strains Isolated in Korea. Osong Public Health Res Perspect (2011) 0.77
Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007. Clin Vaccine Immunol (2013) 0.76
Virulence Factors Variation Among Bordetella Pertussis Isolates in Iran. Int J Mol Cell Med (2015) 0.75
Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun (1998) 3.76
Antigenic relationship between serotype-specific agglutinogen and fimbriae of Bordetella pertussis. Infect Immun (1982) 2.28
Cloning and nucleotide sequence analysis of the serotype 2 fimbrial subunit gene of Bordetella pertussis. Mol Microbiol (1987) 2.23
Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis (2000) 2.05
Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol (2002) 2.02
Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol (2001) 2.02
Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect Immun (2001) 1.64
Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine (1997) 1.63
Persistence of pertussis in an immunized population: results of the Nova Scotia Enhanced Pertussis Surveillance Program. J Pediatr (1989) 1.61
Change in serotype of pertussis infection in Britain. Lancet (1985) 1.60
Whooping cough--a continuing problem. BMJ (2002) 1.43
Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine (2001) 1.42
Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine. Vaccine (1999) 1.33
Analysis of Bordetella pertussis isolates collected in Japan before and after introduction of acellular pertussis vaccines. Vaccine (2001) 1.13
Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine (2002) 1.11
The major fimbrial subunit of Bordetella pertussis binds to sulfated sugars. Infect Immun (1996) 1.10
Structure of the Bordetella pertussis gene coding for the serotype 3 fimbrial subunit. FEMS Microbiol Lett (1990) 1.04
Bordetella pertussis fimbriae bind to human monocytes via the minor fimbrial subunit FimD. J Infect Dis (1995) 1.02
Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization. Infect Immun (2000) 1.00
Epitope mapping the Fim2 and Fim3 proteins of Bordetella pertussis with sera from patients infected with or vaccinated against whooping cough. FEMS Immunol Med Microbiol (1996) 0.94
Bordetella pertussis serotypes in Canada. Can Med Assoc J (1978) 0.88
Bordetella pertussis in the National Capital Region: prevalent serotype and immunization status of patients. Can Med Assoc J (1977) 0.85
Characterization of outbreak and vaccine strains of Bordetella pertussis--Quebec. Can Commun Dis Rep (1993) 0.80
Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA (2013) 4.69
Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA (2010) 4.21
Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003. Thorax (2007) 3.36
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA (2013) 3.06
Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis (2005) 3.06
Ceftiofur resistance in Salmonella enterica serovar Heidelberg from chicken meat and humans, Canada. Emerg Infect Dis (2010) 3.01
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA (2008) 2.88
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J (2013) 2.80
The changing age and seasonal profile of pertussis in Canada. J Infect Dis (2002) 2.53
Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr (2003) 2.42
Human coronavirus NL63 infection in Canada. J Infect Dis (2005) 1.93
Human metapneumovirus infection in the Canadian population. J Clin Microbiol (2003) 1.90
Pandemic influenza in Canadian children: a summary of hospitalized pediatric cases. Vaccine (2010) 1.86
Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol (2009) 1.75
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis (2013) 1.70
Increased burden of illness associated with antimicrobial-resistant Salmonella enterica serotype typhimurium infections. J Infect Dis (2004) 1.69
Outbreak of atypical pertussis detected by polymerase chain reaction in immunized preschool-aged children. Pediatr Infect Dis J (2009) 1.67
Burden of seasonal influenza in children with neurodevelopmental conditions. Pediatr Infect Dis J (2014) 1.63
Surveillance for influenza admissions among children hospitalized in Canadian immunization monitoring program active centers, 2003-2004. Pediatrics (2006) 1.59
Characterization of waterborne outbreak-associated Campylobacter jejuni, Walkerton, Ontario. Emerg Infect Dis (2003) 1.59
Utility of gastric aspirates for diagnosing tuberculosis in children in a low prevalence area: predictors of positive cultures and significance of non-tuberculous mycobacteria. Pediatr Infect Dis J (2015) 1.54
Inadequate pain management during routine childhood immunizations: the nerve of it. Clin Ther (2009) 1.51
Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. CMAJ (2004) 1.50
Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations. Vaccine (2011) 1.48
Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine: A Randomized Controlled Trial. Obstet Gynecol (2016) 1.44
The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J (2009) 1.38
Use of the oxford multilocus sequence typing protocol and sequencing of the flagellin short variable region to characterize isolates from a large outbreak of waterborne Campylobacter sp. strains in Walkerton, Ontario, Canada. J Clin Microbiol (2005) 1.37
Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines (2009) 1.31
Blastomycosis in Ontario, 1994-2003. Emerg Infect Dis (2006) 1.30
The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine (2009) 1.27
Outcome of penicillin-nonsusceptible Streptococcus pneumoniae meningitis: a nested case-control study. Pediatr Infect Dis J (2002) 1.26
Carotid artery dissection as a possible severe complication of pertussis in an adult: clinical case report and review. Clin Infect Dis (2002) 1.26
VanG-type vancomycin-resistant Enterococcus faecalis strains isolated in Canada. Antimicrob Agents Chemother (2006) 1.26
Characterization of ciprofloxacin resistance in Neisseria gonorrhoeae isolates in Canada. Sex Transm Dis (2002) 1.24
Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis (2014) 1.23
Characterization of invasive Haemophilus influenzae disease in Manitoba, Canada, 2000-2006: invasive disease due to non-type b strains. Clin Infect Dis (2007) 1.23
Phenotypic and molecular characterization of clinical isolates of Mycobacterium elephantis from human specimens. J Clin Microbiol (2002) 1.23
The yin and yang of paracetamol and paediatric immunisations. Lancet (2009) 1.22
Estimated cumulative incidence of pandemic (H1N1) influenza among pregnant women during the first wave of the 2009 pandemic. CMAJ (2010) 1.22
Immunization Monitoring Program, Active: a model of active surveillance of vaccine safety. Semin Pediatr Infect Dis (2003) 1.19
Three-year follow-up of protection rates in children given varicella vaccine. Can J Infect Dis (2002) 1.19
Outbreak of serogroup C meningococcal disease caused by a variant of Neisseria meningitidis serotype 2a ET-15 in a community of men who have sex with men. J Clin Microbiol (2003) 1.16
Isolation prevalence of pulmonary nontuberculous mycobacteria in Ontario in 2007. Can Respir J (2011) 1.16
Prevalence of and risk factors for quinolone-resistant Neisseria gonorrhoeae infection in Ontario. CMAJ (2009) 1.14
Method for inactivating and fixing unstained smear preparations of mycobacterium tuberculosis for improved laboratory safety. J Clin Microbiol (2002) 1.14
Comparison of children hospitalized with seasonal versus pandemic influenza A, 2004-2009. Pediatrics (2012) 1.13
Invasive Haemophilus influenzae in Manitoba, Canada, in the postvaccination era. J Clin Microbiol (2006) 1.13
Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics (2011) 1.12
Pertussis Across the Globe: Recent Epidemiologic Trends From 2000 to 2013. Pediatr Infect Dis J (2015) 1.12
Molecular characterization of drug-resistant Mycobacterium tuberculosis isolates from Ontario, Canada. J Antimicrob Chemother (2009) 1.10
Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors. Pediatr Pulmonol (2009) 1.09
Limited genetic diversity in Salmonella enterica serovar Enteritidis PT13. BMC Microbiol (2007) 1.08
Response to the changing epidemiology of meningococcal disease in North America 1945-2010. Hum Vaccin Immunother (2013) 1.08
Pharmacological and Combined Interventions to Reduce Vaccine Injection Pain in Children and Adults: Systematic Review and Meta-Analysis. Clin J Pain (2015) 1.07
Design of oligonucleotide arrays to detect point mutations: molecular typing of antibiotic resistant strains of Neisseria gonorrhoeae and hantavirus infected deer mice. Mol Cell Probes (2003) 1.06
Epidemiology of invasive meningococcal disease with decreased susceptibility to penicillin in Ontario, Canada, 2000 to 2006. Antimicrob Agents Chemother (2010) 1.06
Epidemic of group A Streptococcus M/emm59 causing invasive disease in Canada. Clin Infect Dis (2010) 1.06
Immunochemical studies and genetic background of two Neisseria meningitidis isolates expressing unusual capsule polysaccharide antigens with specificities of both serogroup Y and W135. Can J Microbiol (2008) 1.06
New endemic Legionella pneumophila serogroup I clones, Ontario, Canada. Emerg Infect Dis (2010) 1.05
Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Vaccine (2009) 1.05
The limitations of point of care testing for pandemic influenza: what clinicians and public health professionals need to know. Can J Public Health (2009) 1.05
Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein. Infect Immun (2003) 1.05
Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev (2014) 1.04
Onychomycosis: a critical study of techniques and criteria for confirming the etiologic significance of nondermatophytes. Med Mycol (2005) 1.03
Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics (2004) 1.02
An outbreak of necrotizing enterocolitis associated with a novel clostridium species in a neonatal intensive care unit. Clin Infect Dis (2002) 1.02
Rhinovirus outbreaks in long-term care facilities, Ontario, Canada. Emerg Infect Dis (2010) 1.02
Active tuberculosis among homeless persons, Toronto, Ontario, Canada, 1998-2007. Emerg Infect Dis (2011) 1.02
Substantial morbidity for hospitalized children with community-acquired rotavirus infections: 2005-2007 IMPACT surveillance in Canadian hospitals. Pediatr Infect Dis J (2010) 1.01
Leprosy-like illness in a patient with Mycobacterium lepromatosis from Ontario, Canada. J Drugs Dermatol (2012) 1.01
Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: population-based case-control study. Vaccine (2011) 1.01
Nontuberculous mycobacterial lung infections in Ontario, Canada: clinical and microbiological characteristics. Lung (2010) 1.01
Molecular typing of a Legionella pneumophila outbreak in Ontario, Canada. J Med Microbiol (2007) 1.01
Epidemic of invasive pneumococcal disease, western Canada, 2005-2009. Emerg Infect Dis (2012) 0.99
The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J (2013) 0.98
Heterogeneity of rotavirus testing and admitting practices for gastroenteritis among 12 tertiary care pediatric hospitals: Implications for surveillance. Can J Infect Dis Med Microbiol (2011) 0.98
A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine (2009) 0.98
Going with the flow: legionellosis risk in Toronto, Canada is strongly associated with local watershed hydrology. Ecohealth (2009) 0.97
Role of D-alanylation of Streptococcus gordonii lipoteichoic acid in innate and adaptive immunity. Infect Immun (2007) 0.97
Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation. BMC Public Health (2014) 0.96
Epidemiology of severe pediatric adenovirus lower respiratory tract infections in Manitoba, Canada, 1991-2005. BMC Infect Dis (2012) 0.96
Severe human rhinovirus outbreak associated with fatalities in a long-term care facility in Ontario, Canada. J Am Geriatr Soc (2010) 0.96
Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993-2002. Pediatr Infect Dis J (2004) 0.95
Purification and immunogenicity of a recombinant Bordetella pertussis S1S3FHA fusion protein expressed by Streptococcus gordonii. Appl Environ Microbiol (2002) 0.95
The laboratory diagnosis of Neisseria gonorrhoeae. Can J Infect Dis Med Microbiol (2005) 0.95
Expression of the Streptococcus mutans essential two-component regulatory system VicRK is pH and growth-phase dependent and controlled by the LiaFSR three-component regulatory system. Microbiology (2009) 0.94
The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada. Pediatr Infect Dis J (2007) 0.94
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J (2012) 0.94
Bordetella holmesii, an emerging cause of septic arthritis. J Clin Microbiol (2013) 0.93
Whole-genome sequence of Streptococcus pseudopneumoniae isolate IS7493. J Bacteriol (2011) 0.93
Use of monoclonal antibodies to serotype Bordetella pertussis isolates: comparison of results obtained by indirect whole-cell enzyme-linked immunosorbent assay and bacterial microagglutination methods. J Clin Microbiol (2005) 0.93
Pertussis resurgence in Toronto, Canada: a population-based study including test-incidence feedback modeling. BMC Public Health (2011) 0.93
Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics. PLoS One (2013) 0.93
Increase in ampC promoter strength due to mutations and deletion of the attenuator in a clinical isolate of cefoxitin-resistant Escherichia coli as determined by RT-PCR. J Antimicrob Chemother (2005) 0.93
Profile of serogroup Y meningococcal infections in Canada: Implications for vaccine selection. Can J Infect Dis Med Microbiol (2009) 0.92
Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J (2009) 0.92
Immunization site pain: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine (2012) 0.91
Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies. Vaccine (2013) 0.91